Apealea® (paclitaxel micellar)

Apealea® (paclitaxel micellar)

In December 2020 Inceptua licensed the global commercial rights of Apealea from Elevar Therapeutics Inc.

Apealea (paclitaxel micellar) is a prescription medicine, indicated for the treatment of adult patients with first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer, in combination with carboplatin.

Apealea is a cremophor-free paclitaxel that does not contain polyoxyl caster oil or ethanol and does not require mandatory pre-medication. 

Please always consult local prescribing information and labelling text before use.

For more information about Apealea please refer to the prescribing information: European Medicines Agency

 

Privacy notice

Health Care Professionals and Adverse Event Report Privacy Notice.

Medical Information

If you would like to speak to a medical representative, please contact:

inceptua.mi@primevigilance.com

+49 30 1202 1381

Safety and adverse events

Patient safety is a key priority for us. For any suspected adverse drug reactions associated with Apealea, please contact:

inceptuaPV@primevigilance.com

+49 30 1202 1381

Inceptua Pharma Medicines Access Policy